Murphy G F, Radu A, Kaminer M, Berd D
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia.
J Invest Dermatol. 1993 Mar;100(3):335S-341S. doi: 10.1111/1523-1747.ep12470236.
Human primary malignant melanoma is often accompanied by a host response of infiltrating lymphocytes suggestive of tumor antigen-induced immunity and correlated in some tumors with prognosis. Whereas metastatic melanoma deposits typically are not inflamed and contain relatively few lymphocytes and dendritic immune cells, immunization with autologous melanoma-cell vaccine may induce a clinical inflammatory response associated with mononuclear-cell infiltration. In this study, we characterize immune responses to dermal and subcutaneous melanoma metastases in dinitrophenyl (DNP)-pre-sensitized patients immunized with DNP-conjugated melanoma cells. Patients so treated develop cutaneous delayed hypersensitivity responses to DNP-conjugated autologous mononuclear cells, and approximately one-half show clinical evidence of inflammation and regression of metastases within 2-4 months. Whereas pre-vaccination biopsies of metastatic melanoma failed to reveal significant infiltration by lymphocytes, biopsies obtained after vaccination and coincident with clinical inflammation were markedly infiltrated preponderantly by T cells with a CD8+ phenotype. Clustering of these cells about individual degenerating melanoma cells in a manner analogous to "satellitosis" was a consistent feature of this reaction. Enhanced expression of intercellular adhesion molecule-1 (ICAM-1) and human leukocyte antigen (HLA)-DR by melanoma cells were invariably associated with zones of T-cell infiltration, whereas diminished or absent expression was observed in relatively unaffected regions of tumors. Numerous HLA-DR+, CD4+, CD1-, Leu-1- dendritic cells were also associated with zones of early T-cell infiltration. These data indicate that clinical inflammation and regression of metastatic melanoma induced by autologous melanoma-cell vaccine involves activated T cells with cytotoxic-suppressor phenotype and dendritic cells putatively capable of local antigen presentation. ICAM-1 upregulation on melanoma cells is a likely mediator of ligand interaction between infiltrating T cells and target cells in this model of antigen-induced host anti-tumor response. Structural alterations identified in this setting (e.g., tumor cell satellitosis) may provide additional insight into identifying features of naturally occurring host immune responses to primary cutaneous melanomas.
人类原发性恶性黑色素瘤常伴有浸润淋巴细胞的宿主反应,提示肿瘤抗原诱导的免疫反应,且在某些肿瘤中与预后相关。转移性黑色素瘤沉积物通常无炎症,淋巴细胞和树突状免疫细胞相对较少,而用自体黑色素瘤细胞疫苗免疫可诱导与单核细胞浸润相关的临床炎症反应。在本研究中,我们对用二硝基苯基(DNP)偶联的黑色素瘤细胞免疫的DNP预致敏患者的皮肤和皮下黑色素瘤转移灶的免疫反应进行了表征。接受这种治疗的患者对DNP偶联的自体单核细胞产生皮肤迟发型超敏反应,约一半患者在2 - 4个月内出现炎症和转移灶消退的临床证据。虽然转移性黑色素瘤的疫苗接种前活检未显示淋巴细胞有明显浸润,但接种疫苗后与临床炎症同时进行的活检显示,主要是CD8 + 表型的T细胞明显浸润。这些细胞以类似于“卫星现象”的方式围绕单个退化的黑色素瘤细胞聚集是这种反应的一个一致特征。黑色素瘤细胞细胞间黏附分子-1(ICAM-1)和人类白细胞抗原(HLA)-DR的表达增强总是与T细胞浸润区域相关,而在肿瘤相对未受影响的区域观察到表达减少或缺失。许多HLA-DR + 、CD4 + 、CD1 - 、Leu-1 - 树突状细胞也与早期T细胞浸润区域相关。这些数据表明,自体黑色素瘤细胞疫苗诱导的转移性黑色素瘤的临床炎症和消退涉及具有细胞毒性抑制表型的活化T细胞和可能能够进行局部抗原呈递的树突状细胞。在这种抗原诱导的宿主抗肿瘤反应模型中,黑色素瘤细胞上ICAM-1的上调可能是浸润T细胞与靶细胞之间配体相互作用的介质。在这种情况下发现的结构改变(如肿瘤细胞卫星现象)可能为识别天然宿主对原发性皮肤黑色素瘤的免疫反应特征提供更多见解。